Title: Numinus Focuses on Clinics, Study Shows DMT In Combination with SSRI, Preprint Challenges Theory of Psychedelic Neuroplasticity, Potential for Regulations Similar to Cole Memo in Psychedelics
Summary:
1. Numinus, a Vancouver-based company, announces plans to reduce cash expenses by closing down its non-revenue-producing research lab and consolidating clinics. The company will focus on clinics, training, and clinical research sites going forward.
2. Small Pharma’s Phase 2a trial suggests that DMT is safe and effective when administered to patients with major depressive disorder who are on selective serotonin reuptake inhibitors (SSRIs). The study demonstrates strong efficacy signals and a significant difference in remission rates between those on SSRIs and those who are not.
3. A potential Cole Memo for psychedelics is introduced by Earl Blumenauer and Robert Garcia, proposing a law that would prohibit the use of federal funds to prevent states from implementing their own psilocybin laws. While this is a start, the proposed law only covers psilocybin and does not include other psychedelic substances or broader drug decriminalization efforts.
4. A preprint challenges the intracellular theory of psychedelic-induced neuroplasticity, suggesting that the extracellular theory may have been correct. This study provides important insights into the mechanisms of action of psychedelics and could impact future research in the field.
5. The bulletin also includes updates on the psychedelic sector, such as the projected market value, job openings, and recent studies and developments in the field.
